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136(68%) and residual abnormality either clinical or 
radiological were seen in 64(32%). Immediate salvage surgery 
was carried out in 38(60%) patients with progressive residual 
disease who were fit. Eight (21%) had no pathological residual 
disease (ypT0). Surgery was withheld in further 8 (4%) out of 
64 without progression of residual abnormality. Those with 
cCR 116(85%) maintained complete response. Sixteen (11.7%) 
developed local relapse after cCR. Early staged tumors 
respond better with less local and total relapse. At median 
follow up of 2.49 months following completion of treatment; 
complete remission was achieved in 160 (80%) patients , 
12(6%) had asymptomatic static disease and 28 (14%) had 
progressive residual disease but not fit for salvage surgery 
due to age or medical co-morbidity. The main toxicity was 
bleeding occurring in 30% of cases and 10% needed argon 
beam. Organ preservation for the whole group was achieved 
in 158 (79%). Overall Survival (94% vs. 76%) [p=0.02] was 
better for responders (cCR +SD) at 2 years.  
 
Conclusion: CXB (Papillon) boost reduced local recurrence to 
11.7% after achieving cCR compared to 30-40% in those who 
had EBCRT alone. Organ preservation of 79% for the whole 
group is much higher than any ‘watch and wait’ studies with 
40% published so far. A randomised trial OPERA has been set 
up to evaluate this further. Papillon has acceptable toxicity 
and is now recommended by NICE for patients not suitable 
for surgery. Papillon should be consider as a treatment option 
for elderly patients with early rectal cancer. 
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Purpose or Objective: The programmed death ligand 1 (PD-
L1) plays a key role in tumour progression and metastasis of 
pancreatic ductal adenocarcinoma (PDAC). Although recent 
preclinical studies have explored the radiosensitising 
potential of PD-1/PD-L1 inhibitors, the effect of PD-L1 
blockade on the response of PDAC to radiotherapy remains 
unexplored. 
 
Material and Methods: Herein, we investigated the influence 
of an anti-PD-L1 mAb on the tumour response to single dose 
and fractionated radiotherapy, and chemotherapy with 
gemcitabine and capecitabine. 
 
Results: In-vitro, radiation and chemotherapy resulted in PD-
L1 upregulation in both human (PSN-1) and murine (KPC-
derived, Pan02) PDAC cells, although variability was 
observed. Exposure to conditioned media from pre-treated 
cells did not alter PD-L1 expression. In-vivo, PD-L1 was also 
upregulated in the tumour microenvironment after radiation 
and chemotherapy in the KPC-derived and Pan02 syngeneic 
mouse models. Similarly, chemotherapy induced PD-L1 
upregulation in the KPC (Pdx1Cre, KRASG12D/+, 
P53R172H/+), a genetically-engineered mouse model of 
pancreatic cancer. In-vitro, PD-L1 blockade failed to radio- or 
chemosensitise PDAC cells. The anti-PD-L1 mAb significantly 
improved tumour response after irradiation in the KPC and 
Pan02 syngeneic mouse models. This effect was mediated by 
a cytotoxic T cell-dependent mechanism, whereas blockade 
of CD8+ cells attenuated the radiosensitising potential of 
anti-PD-L1. The effect of scheduling of anti-PD-L1 mAb with 
radiotherapy (concomitant vs sequential) was also 
investigated. Finally, we assessed the intratumoural and 
systemic expression of several immune markers (CD45+: CD8, 
CD4, CD19, NK1.1, CD11b Gr1, Ly6G, CXCR2, FOXP3, IFN-γ) 
after the different treatments. 
 
Conclusion: Altogether, our findings support PD-L1 inhibition 
in combination with radiation as a promising approach in the 
treatment of PDAC. 
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Purpose or Objective: In this work, the design, fabrication, 
and operation of a small-scale graphite calorimeter probe 
(GPC) developed for use as a practical clinical dosimeter, is 
described. Similar in size and shape to a Farmer-type 
cylindrical ionization chamber, the GPC represents the first 
translation of calorimetry from the primary standards 
dosimetry laboratory to the radiotherapy clinic. Providing a 
measure of absolute dose, its purpose is to help meet the 
clinical need for accurate reference dosimetry in non-




Material and Methods: Based on a numerically-optimized 
design obtained in previous work, a functioning prototype 
capable of two independent modes of operation (constant-
power & constant-temperature) was constructed in-house. In 
constant-power mode, the radiation-induced temperature 
rise, ΔT, is measured in the sensitive volume (i.e. the core) 
while the outermost portion of the device is thermally 
stabilized by a software-based temperature controller. In 
constant-temperature mode, the entire device is subject to 
active thermal control and the quantity of interest is the 
electrical power, ΔP, necessary to maintain a stable 
temperature while irradiated. 
Absorbed dose to water measurements were performed in a 
water phantom, under standard conditions, using both GPC 
operation modes in a 6 MV photon beam and subsequently 
compared to dose to water measurements derived using a 
reference-class ionization chamber (Exradin A12). Linearity, 
dose rate, and field size dependence were evaluated by 
varying the irradiation period, the linac repetition rate, and 
primary collimating jaw settings, respectively. 
 
Results: Compared to the chamber-derived dose to water of 
0.765 cGy/MU, the average GPC-measured doses were 0.765 
± 0.005 (n = 25) and 0.769 ± 0.005 (n = 32) cGy/MU for the 
constant-power and constant-temperature modes, 
respectively. 
The linearity of the detector response was characterized by 
an adjusted R² value of 0.9996 (n = 40), and no 
statistically-significant dose rate dependence for rates 
greater than 1.8 Gy/min was observed. For lower dose rates, 
an over response of 1.7 % was attributed to the resolution of 
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the current-driven temperature controller. No field size 




Conclusion: This work demonstrates the feasibility of using 
an ion chamber-sized calorimeter as a practical means of 
measuring absolute dose to water in the radiotherapy clinic. 
The potential introduction of calorimetry into the clinical 
setting is significant as this fundamental technique has 
formed the basis of absorbed dose standards in many 
countries for decades. Considered as the most direct means 
of measuring dose, a “calorimeter for the people” could play 
an important role in solving the major challenges of 
contemporary dosimetry. In particular, investigations into the 
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Purpose or Objective: Build-up material is commonly used in 
electron beam radiation therapy to overcome the skin sparing 
effect and to homogenise the dose distribution in case of 
irregular skin surfaces. Often, an individualised bolus is 
necessary. This process is complex and highly labour-
intensive, while adaptation of the bolus is time consuming. 
We implemented a new clinical workflow in which the bolus 
is designed on the CT scan in the treatment planning system 
(TPS). Subsequently a cast with the bolus shape is 3D-printed 
and filled with silicone rubber to create the bolus itself [1]. 
 
Material and Methods: In the new workflow (figure 1), a 
patient-specific bolus is designed in the TPS. A 2 mm 
expansion is used to create a cast around the bolus. 
Subsequently, this cast is smoothed to remove CT scan 
resolution effects. After conversion to a stereolithography 
file, the cast is printed in polylactic acid (PLA) with a 
filament printer and filled with silicone rubber. After removal 
of the PLA cast, the bolus is ready for clinical use. 
Before clinical implementation we performed a planning 
study with 11 patients to evaluate the difference in tumour 
coverage with a 3D-print bolus in comparison to the clinically 
delivered plan with a manually created bolus.  
During clinical implementation of the 3D-print workflow, for 
7 patients a second CT-scan with the 3D-print bolus in 
position was made to assess its geometrical accuracy and the 
resulting dose distribution. 
 
Results: The planning study showed at least equal coverage 
of GTV and CTV: V95% of the GTV was on average 97% (3D-
print) vs 84% (conventional). V85% of the CTV was on average 
97% (3D-print) vs 88% (conventional).  
Geometric comparison of the 3D-print bolus to the originally 
contoured bolus showed a high similarity (mean dice 
similarity coefficient of 0.87 (range 0.81 to 0.95).  
Comparison of the dose distributions at the planning CT scan 
to dose distributions at the second CT scan with the 3D print 
bolus in position showed only small differences (median 
difference in V95% GTV and V85% CTV of 0% (interquartile 
range: -12% to 0%) and -1.6% (interquartile range: -3.8 to 
0.5%), respectively).  
Time efficiency of the 3D-print workflow is likely to increase 
in comparison to the conventional workflow, with one less 
patient visit, and up to 3 hours less mould room time. 
 
Conclusion: The implemented workflow is feasible, patient 
friendly, safe, and results in high quality dose distributions. 
This new technique increases time efficiency and logistically 




Figure 1: Illustration of the clinically implemented 3D-print 
workflow with designed bolus(A) and cast around the bolus(B) 
at the planning CT scan, smoothed cast (C), 3D model of the 
cast (D), printed cast (E) and silicone rubber final bolus (F).  
1. Holtzer, N.A., et al., 3D printing of tissue equivalent 
boluses and molds for external beam radiotherapy, Estro 33. 
2014: Vienna. 
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Radiation oncology is a rapidly evolving profession requiring 
continuous learning on the top of all routine activities. 
Residency is a unique period in a professional life where the 
main objective is to learn. Residency is full of research and 
educational opportunities for young radiation oncologists to 
gain know-how and expertise in clinical practice, patient 
care, fundamental, translational and/or clinical research and 
innovative technologies in the various aspects of our 
specialty. Through local, national and international 
programs, trainees gain valuable clinical and research 
experience and skills during and rapidly get the opportunity 
to disseminate information and update colleagues in their 
home institution. Playing a proactive role in the training will 
not only give access to the best training opportunities but 
will motivate as well supervisors in supporting trainee’s 
career development. 
In a competitive world with limited resources, building up 
good curriculum vitae with a number of publications and 
presentations is a major advantage that should be 
